

BIOENVISION INC  
Form SC 14D9/A  
June 18, 2007

## **SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

### **SCHEDULE 14D-9**

**SOLICITATION/RECOMMENDATION STATEMENT**

**PURSUANT TO SECTION 14(d)(4) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**(Amendment No. 3)**

**BIOENVISION, INC.**

(Name of Subject Company)

**BIOENVISION, INC.**

(Name of Person(s) Filing Statement)

**Common Stock, par value \$0.001 per share**

**(including the associated preferred stock purchase rights)**

**Series A Convertible Participating Preferred Stock, par value \$0.001 per share**

(Title of Class of Securities)

**09059N100**

(CUSIP Number of Common Stock)

**David P. Luci**

**345 Park Avenue, 41st Floor**

**New York, New York 10154**

**(212) 750-6700**

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of the Person(s) Filing Statement)

**With copies to:**

**Christopher J. Denn, Esq.**

**James R. Kasinger, Esq.**

**Goodwin Procter LLP**

**Exchange Place**

**Boston, Massachusetts 02109-2881**

**(617) 570-1000**

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

This Amendment No. 3 ( Amendment No. 3 ) amends the Solicitation/Recommendation Statement on Schedule 14D-9, as originally filed with the Securities and Exchange Commission ( SEC ) on June 7, 2007 and amended by Amendment No. 1 on June 12, 2007 and Amendment No. 2 on June 15, 2007 (the Schedule 14D-9 ) by Bioenvision, Inc., a Delaware corporation (the Company ). The Schedule 14D-9 and this Amendment No. 3 relate to the tender offer (the Offer ) by Wichita Bio Corporation, a Delaware corporation (the Purchaser ) and a wholly-owned subsidiary of Genzyme Corporation, a Massachusetts corporation ( Genzyme ), as disclosed in a Tender Offer Statement on Schedule TO, dated June 4, 2007 (the Schedule TO ), filed by the Purchaser and Genzyme, to purchase all the outstanding shares of Common Stock, par value \$0.001 per share, including associated preferred stock purchase rights (the Common Shares ), of the Company, at a purchase price of \$5.60 per Common Share, net to the seller in cash, without interest thereon, less any applicable withholding taxes, and to purchase all outstanding shares of the Company s Series A Convertible Participating Preferred Stock, par value \$0.001 per share (the Series A Preferred Shares, and together with the Common Shares, the Shares ) at a purchase price of \$11.20 per Series A Preferred Share, net to the seller in cash, plus all accrued but unpaid dividends, without interest thereon, less any applicable withholding taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase dated June 4, 2007 (the Offer to Purchase ) and in the related Letter of Transmittal (the Letter of Transmittal which, together with the Offer to Purchase, as each may be amended and supplemented from time to time, constitute the Offer ). The Offer to Purchase and the Letter of Transmittal were filed as Exhibits (a)(1)(A) and (a)(1)(B), respectively, to the Schedule 14D-9.

The Offer is being made pursuant to the Agreement and Plan of Merger dated as of May 29, 2007 (the Merger Agreement ), among Genzyme, Purchaser and the Company, pursuant to which, following the consummation of the Offer and the satisfaction or waiver of certain conditions, Purchaser will be merged with and into the Company, with the surviving entity, the Company, becoming a direct wholly-owned subsidiary of Genzyme (the Merger ).

Capitalized terms used, but not otherwise defined, in this Amendment No. 3 shall have the meanings given in the Schedule 14D-9. All information in the Schedule 14D-9 is incorporated by reference in this Amendment No. 3, except that such information is hereby amended to the extent specifically provided herein.

#### **Item 8. Additional Information.**

Item 8 of Schedule 14D-9 is hereby amended by adding the following to the end of such section:

#### **(i) Certain Legal Proceedings.**

On June 14, 2007, a purported shareholder of the Company filed a purported class action lawsuit in the Court of Chancery in the State of Delaware, New Castle County docketed as *Albstein v. Bioenvision, Inc., et. al.* Civ. A. No. 3025 (the Action ) against the Company, each of its directors, Genzyme and Purchaser. The Action purports to be brought individually and on behalf of all holders of Common Shares. The Action alleges that the director defendants breached their fiduciary duties to the Company s shareholders in connection with the Offer and that Genzyme aided and abetted such alleged breach of the director defendants fiduciary duties. Based on these allegations, the Action seeks, among other relief, injunctive relief preliminarily and permanently enjoining each of the Company, its directors, Genzyme and Purchaser from consummating the Offer and the Merger, directing the director defendants to exercise their fiduciary duties to obtain a transaction that is in the best interests of the Company s

shareholders, and rescinding, to the extent already implemented, the Offer and the Merger or any of the terms thereof. The Company and the Company's Board of Directors believe the allegations in the Action are without merit.

A copy of the complaint in this Action is attached hereto as Exhibit (e)(16) and is hereby incorporated herein by reference. The foregoing description is qualified in its entirety by reference to Exhibit (e)(16).

**Item 9. Exhibits.**

Item 9 of Schedule 14D-9 is hereby amended by adding the following exhibit:

Exhibit

No.	Description
(e)(16)	Complaint filed by Andrew W. Albstein, on behalf of himself and all other public shareholders of Bioenvision, Inc., on June 14, 2007, in the Court of Chancery in the State of Delaware, New Castle County.

---

**SIGNATURE**

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: June 18, 2007

BIOENVISION, INC.

By: /s/ Christopher B. Wood  
Christopher B. Wood  
Chairman and Chief Executive Officer

---